Market Spotlight: Esophageal Cancer
Market Spotlight: Esophageal Cancer
$1,318.00
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways:
- Datamonitor Healthcare estimates that in 2019, there were 578,600 incident cases of esophageal cancer worldwide, and expects that number to increase to 618,900 incident cases by 2028.
- Incidence is higher in males compared to females, and is highest in the Asia region. Merck & Co’s Keytruda, Pinnacle Biologics’ Photofrin, Bristol Myers Squibb’s Opdivo, and Jiangsu Hengrui’s camrelizumab are the only marketed drugs for esophageal cancer. These drugs are administered via the intravenous route.
- The largest proportion of industry-sponsored drugs in active clinical development for esophageal cancer are in Phase II. Therapies in development for esophageal cancer focus on a wide variety of targets. The majority of pipeline drugs are administered intravenously, with the remainder being oral and intratumoral formulations.
- High-impact upcoming events for drugs in the esophageal cancer space comprise topline Phase II trial results for ADPA2M4CD8, topline Phase III trial results for Imfinzi, and an expected supplemental CHMP opinion for Opdivo.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.3%, and the average probability a drug advances from Phase III is 42.8%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for esophageal cancer have been in the early and mid-phases of development, with 91% of trials in Phase I–II, and only 9% in Phase III–IV.
- The US has a substantial lead in the number of esophageal cancer clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the esophageal cancer space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for esophageal cancer, with 93 trials.
- Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for esophageal cancer, closely followed by Roche
CONTENTS
7 OVERVIEW
8 KEY TAKEAWAYS
9 DISEASE BACKGROUND
10 TREATMENT
10 Surgery
10 Radiation therapy
10 Endoscopic therapy
11 Chemotherapy
11 Targeted therapy
11 Immunotherapy
13 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 Sintilimab for Esophageal Cancer (June 22, 2021)
27 Tislelizumab for Esophageal Cancer (June 4, 2021)
28 Opdivo for Esophageal Cancer (June 3, 2021)
30 Camrelizumab for Esophageal Cancer (May 28, 2021)
31 Tislelizumab for Esophageal Cancer (January 27, 2021)
33 Keytruda for Esophageal Cancer (September 21, 2020)
35 Opdivo for Esophageal Cancer (September 21, 2020)
37 Opdivo for Esophageal Cancer (September 21, 2020)
39 Keytruda for Esophageal Cancer (August 19, 2020)
40 Opdivo for Esophageal Cancer (August 11, 2020)
42 Opdivo for Esophageal Cancer (August 11, 2020)
43 Yervoy for Esophageal Cancer (August 11, 2020)
46 KEY UPCOMING EVENTS
47 KEY REGULATORY EVENTS
47 Keytruda’s Third-Line Gastric Cancer Indication Should Go, US FDA Panel Says
47 Opdivo First-Line Gastric Cancer Claim Used RTOR
47 Merck Builds Keytruda Esophageal Carcinoma Label Under RTOR
47 Opdivo Seeks New Gastric Cancer Uses
48 New Submission For Keytruda In Esophageal Cancer
48 Opdivo First In Gastroesophageal Cancer
49 PROBABILITY OF SUCCESS
50 LICENSING AND ASSET ACQUISITION DEALS
50 Amcure Partners Esophageal Cancer Drug In China With Hinova
50 Pfizer Bets $480m On CStone And Surging China Immuno-Oncology Market
50 AbbVie and China’s Jacobio Pharmaceuticals Unveil Collaboration
51 REVENUE OPPORTUNITY
52 CLINICAL TRIAL LANDSCAPE
53 Sponsors by status
54 Sponsors by phase
55 Recent events
58 BIBLIOGRAPHY
59 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of esophageal cancer, 2019–28
15 Figure 2: Incident cases of esophageal cancer, by gender, 2019
19 Figure 3: Overview of pipeline drugs for esophageal cancer in the US
19 Figure 4: Pipeline drugs for esophageal cancer, by company
20 Figure 5: Pipeline drugs for esophageal cancer, by drug type
20 Figure 6: Pipeline drugs for esophageal cancer, by classification
27 Figure 7: Sintilimab for Esophageal Cancer (June 22, 2021): Phase III – ORIENT-15 (Global)
28 Figure 8: Tislelizumab for Esophageal Cancer (June 4, 2021): Phase III – RATIONALE 302
30 Figure 9: Opdivo for Esophageal Cancer (June 3, 2021): Phase III – CheckMate 648
33 Figure 10: Tislelizumab for Esophageal Cancer (January 27, 2021): Phase III – RATIONALE 302
35 Figure 11: Keytruda for Esophageal Cancer (September 21, 2020): Phase III – KEYNOTE-590
37 Figure 12: Opdivo for Esophageal Cancer (September 21, 2020): Phase III – CheckMate-649
39 Figure 13: Opdivo for Esophageal Cancer (September 21, 2020): Phase III – CheckMate-577
40 Figure 14: Keytruda for Esophageal Cancer (August 19, 2020): Phase III – KEYNOTE-590
42 Figure 15: Opdivo for Esophageal Cancer (August 11, 2020): Phase III – CheckMate-577
43 Figure 16: Opdivo for Esophageal Cancer (August 11, 2020): Phase III – CheckMate-649
45 Figure 17: Yervoy for Esophageal Cancer (August 11, 2020): Phase III – CheckMate – 649 (w/Nivolumab)
46 Figure 18: Key upcoming events in esophageal cancer
49 Figure 19: Probability of success in the solid tumors pipeline
52 Figure 20: Clinical trials in esophageal cancer
52 Figure 21: Top 10 drugs for clinical trials in esophageal cancer
53 Figure 22: Top 10 companies for clinical trials in esophageal cancer
53 Figure 23: Trial locations in esophageal cancer
54 Figure 24: Esophageal cancer trials status
55 Figure 25: Esophageal cancer trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of esophageal cancer, 2019–28
17 Table 2: Marketed drugs for esophageal cancer
21 Table 3: Pipeline drugs for esophageal cancer in the US
26 Table 4: Sintilimab for Esophageal Cancer (June 22, 2021)
27 Table 5: Tislelizumab for Esophageal Cancer (June 4, 2021)
29 Table 6: Opdivo for Esophageal Cancer (June 3, 2021)
31 Table 7: Camrelizumab for Esophageal Cancer (May 28, 2021)
32 Table 8: Tislelizumab for Esophageal Cancer (January 27, 2021)
34 Table 9: Keytruda for Esophageal Cancer (September 21, 2020)
36 Table 10: Opdivo for Esophageal Cancer (September 21, 2020)
38 Table 11: Opdivo for Esophageal Cancer (September 21, 2020)
39 Table 12: Keytruda for Esophageal Cancer (August 19, 2020)
41 Table 13: Opdivo for Esophageal Cancer (August 11, 2020)
42 Table 14: Opdivo for Esophageal Cancer (August 11, 2020)
44 Table 15: Yervoy for Esophageal Cancer (August 11, 2020)
51 Table 16: Historical global sales, by drug ($m), 2016–20
51 Table 17: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Acne 
Sign up to the